key: cord-0030765-4q6su1h8
authors: Okura, Hiroyuki
title: Update of takotsubo syndrome in the era of COVID-19
date: 2021-02-03
journal: J Cardiol
DOI: 10.1016/j.jjcc.2021.01.014
sha: 5584b8532bd1536eb39bd2039cf2eb6155c1581f
doc_id: 30765
cord_uid: 4q6su1h8

nan

Is modulation (desensitization) of the beta-adrenergic receptors a cause or an epiphenomenon of takotsubo syndrome?

To the Editor, I enjoy very much reading the review by Okura about takotsubo syndrome (TTS) and the COVID-19 era [1] . I am particularly interested in engaging the authors in respect to the speculation that modulation (desensitization) of the beta-adrenergic receptors (BARs) could be a possible mechanism for the transiently depressed myocardial contraction abnormalities seen in TTS, and thus providing some explanation of its pathophysiology. Certainly, catecholamines either blood-borne (mainly epinephrine) or locally secreted at the cardiomyocyte site (mainly norepinephrine), must be essential in the pathophysiology of TTS [2] , and Kume et al., with Okura among the authors, via their study with sampling for catecholamines from the aortic root and coronary sinus, have provided seminal information about the primary role played by norepinephrine [3] . The authors further on in the section on "Pathophysiology and mechanisms of TTS" of their review refers to two different views about a plausible pathophysiological mechanism causing TTS by: (1) citing the animal work of Paur et al. [4] , wherein the inciting mechanism of apical cardiodepression/cardioprotection, causing apical akinesis/dyskinesis is mediated by a high level of blood-borne epinephrine leading to a switch of the canonical β2-AR coupling from Gs protein (cardiostimulatory) to Gi protein (cardioinhibitory) effects on the cardiomyocytes; and (2) discussing the in vivo work of Nakano et al., with Okura among the authors, where a β1-AR alteration modulation (desensitization) is induced in TTS, as assessed from biopsies in TTS patients showing "more abundantly expressed G protein coupled receptor kinase 2 (GRK2) and β-arrestin2, both of which are known to desensitize β-AR [5] .

Of course, the above 2 pathophysiologic mechanisms should be scrutinized in the light of: (1) topographic concentration of the β1-AR and β2-AR in different myocardial territories, and the morphological imaging phenotypes (i.e. apical, mid-ventricular, reverse, focal, global, right ventricular), encountered in clinical cases of TTS;

(2) the changing morphological imaging phenotypes in recurrent episodes of TTS, occurring days, weeks, years apart; (3) the changing morphological imaging phenotypes occurring hours or days apart within the same episode of TTS; and the timing of the assessment (e.g. left ventricular biopsy) of the BARs in the course of the TTS episode (i.e., hyperacute, acute, subacute, follow-up stage).

The authors refer to the work of Akashi et al. (Y.J. Akashi, K. Nakazawa, M. Sakakibara, F. Miyake, H. Musha, K. Sasaka. 123I-MIBG myocardial scintigraphy in patients with "takotsubo" car-diomyopathy. J Nucl Med, 45 (2004), pp. 1121-1127) , who showed an increase of the iodine-123-meta-iodobenzylguanidine uptake and washout ratio in the acute phase of TTS, which indicates enhanced cardiac sympathetic hyperactivity, while decrease in the 123I-MIBG uptake was found in myocardial scintigraphy performed later in the clinical course of TTS, with eventual recovery at longterm follow-up imaging. This suggests changes in the function of the BARs, depending on the timeline of the TTS episode. Also, one wonders whether the modulation (desensitization) of BARs constitute an epiphenomenon rather than the cause of the TTS phenotype, in the sense that such changes occur in the aftermath of damage of the cardiomyocytes, imparted by excessive catecholamine stimulation. Finally, this author questions whether depressed myocardial contraction in TTS could be attributed to modulation (desensitization) of BARs, since BARs are not essential in the cardiac contractile function, except when enhanced functional requirements are called for.

Nothing to disclose.

No funding was received for this work.

Update of takotsubo syndrome in the era of COVID-19

Blood norepinephrine/epinephrine/dopamine measurements in 108 patients with takotsubo syndrome from the world literature: pathophysiological implications

Local release of catecholamines from the hearts of patients with tako-tsubo-like left ventricular dysfunction

High levels of circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent manner: a new model of takotsubo cardiomyopathy

Alteration of beta-adrenoceptor signaling in left ventricle of acute phase takotsubo syndrome: a human study

Update of takotsubo syndrome in the era of COVID-19

Alteration of beta-adrenoceptor signaling in left ventricle of acute phase takotsubo syndrome: a human study